Catalyst Event
Natera Inc (NTRA) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/29/2026, 12:00:00 AM
Scheduled to announce a collaboration with Diakonos Oncology for a Phase I/II clinical trial on 2026-05-29; Low importance due to expected >1% price impact from clinical collaboration scheduled.
Korean Translation
2026년 5월 29일, 불응성 흑색종 임상시험을 위해 Diakonos Oncology와 협력할 예정임. 임상 협력으로 1% 이상의 주가 영향이 예정됨.
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM